InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 21, 2024

https://www.globenewswire.com/news-release/2024/05/21/2885964/0/en/InflaRx-Presents-New-Analysis-of-PANAMO-Phase-III-Trial-in-Severe-COVID-19-at-ATS-2024-Showing-Potential-Synergy-With-Vilobelimab-When-Used-in-Combination-with-Other-Immunomodulato.html

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.